Motawea Mohamad, Khalel Mayada S, Kandil Ismail, Faheem Ahmed Mohsen, Zaki Maysaa El Sayed, Abdelsalam Mostafa, Kyrillos Fady
Diabetes and Endocrinology, Faculty of Medicine, Mansoura University, Mansoura 35516, Egypt.
Internal Medicine Department, Faculty of Medicine, Mansoura University, Mansoura 35516, Egypt.
Diagnostics (Basel). 2025 Jun 13;15(12):1504. doi: 10.3390/diagnostics15121504.
Diabetic nephropathy (DN) is a serious complication of diabetes mellitus. This clinical condition is diagnosed through the detection of microalbuminuria. Molecular biomarkers such as MicroRNA-192 may play a role in the early diagnosis of this condition. This study aims to compare the serum concentrations of MicroRNA-192 in diabetic patients with and without DN and in healthy individuals. This study was a retrospective case-control study that included three groups. Group I included diabetic patients without DN, Group II included patients with DN, and Group III included healthy control subjects. Blood samples were obtained from each participant and subjected to a full biochemical study including creatinine, albumin, and the detection of MicroRNA-192 by real-time polymerase chain reaction. There were significant differences among the MicroRNA-192 levels in the three groups (-0.001). There was a significant increase in the MicroRNA-192 level in Group I (1.35 ± 7 0.5) compared with Group II (0.65 ± 7 0.2, 3 = 0.001) and Group III (0.83 ± 7 0.3, 1-0.001). There was a significant reduction in the MicroRNA-192 level in Group II compared with Group III (2-0.001). This study highlights the potential role of serum miR-192 as a noninvasive biomarker for the early detection of DN in patients with type 2 DM. Our findings demonstrated that serum miR-192 levels were significantly reduced in patients with DN compared with diabetic patients without nephropathy and healthy controls, suggesting the possible protective role of miR-192 in early disease stages.
糖尿病肾病（DN）是糖尿病的一种严重并发症。这种临床病症通过检测微量白蛋白尿来诊断。诸如微小RNA - 192等分子生物标志物可能在该病症的早期诊断中发挥作用。本研究旨在比较患有和未患有DN的糖尿病患者以及健康个体中微小RNA - 192的血清浓度。本研究是一项回顾性病例对照研究，包括三组。第一组包括未患DN的糖尿病患者，第二组包括患有DN的患者，第三组包括健康对照者。从每位参与者采集血样，并进行全面的生化研究，包括肌酐、白蛋白检测以及通过实时聚合酶链反应检测微小RNA - 192。三组之间微小RNA - 192水平存在显著差异（-0.001）。与第二组（0.65±7 0.2，P = 0.001）和第三组（0.83±7 0.3，P = 0.001）相比，第一组中微小RNA - 192水平显著升高（1.35±7 0.5）。与第三组相比，第二组中微小RNA - 192水平显著降低（P = 0.001）。本研究强调了血清miR - 192作为2型糖尿病患者DN早期检测的非侵入性生物标志物的潜在作用？我们的研究结果表明，与未患肾病的糖尿病患者和健康对照相比，DN患者血清miR - 192水平显著降低，提示miR - 192在疾病早期可能具有保护作用。
